![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Atara to Suspend Development of Protein Energy Wasting Treatment
Atara to Suspend Development of Protein Energy Wasting Treatment
December 18, 2015
Atara Biotherapeutics is suspending further development of PINTA 745 for the treatment of protein energy wasting in patients with end-stage renal disease after the candidate fell short of its goal in a Phase 2 trial.
Atara says it will shift its focus to its portfolio of clinical stage oncology and immunotherapy product candidates.
Upcoming Events
-
21Oct